8-KMaterial AgreementsFinancial EventsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (May 3, 2019)

Filed May 3, 2019For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on May 3, 2019, primarily to disclose amendments and restatements of agreements related to lease financing for a facility. These "A&R Agreements" (Amended and Restated Participation Agreement, Lease, and Guaranty) supersede prior agreements from March 2017. The key takeaway for investors is the restructuring of existing lease financing arrangements rather than the initiation of new debt or a material change in the company's financial obligations. The filing indicates that the company, through its subsidiaries, has entered into updated lease agreements for a specific facility. The amendments and restatements involve the lessee (Old Saw Mill Holdings LLC), the lessor (BA Leasing BSC, LLC), the administrative agent (Bank of America, N.A.), and the lenders. The fact that Regeneron Pharmaceuticals, Inc. and other subsidiaries are acting as guarantors reinforces the company's commitment to these financing obligations.

Key Highlights

  • 1Regeneron amended and restated existing lease financing agreements for a facility.
  • 2The new agreements replace those originally entered into in March 2017.
  • 3Key legal documents involved include an Amended and Restated Participation Agreement, an Amended and Restated Lease and Remedies Agreement, and an Amended and Restated Guaranty.
  • 4Old Saw Mill Holdings LLC remains the lessee, and BA Leasing BSC, LLC remains the lessor.
  • 5Regeneron Pharmaceuticals, Inc. and its subsidiaries (Regeneron Healthcare Solutions, Inc., Regeneron Genetics Center LLC) are acting as guarantors for these obligations.
  • 6This filing is primarily procedural, updating existing financial arrangements rather than announcing new debt or significant operational changes.

Frequently Asked Questions

The main purpose of this 8-K filing is to report the amendment and restatement of existing lease financing agreements for a facility. These are updated versions of agreements that were originally put in place in March 2017.

No, this filing does not indicate new debt. It concerns the amendment and restatement of existing lease financing arrangements, meaning the company is updating the terms of a previously established financial obligation, not creating a new one.

The parties involved include Old Saw Mill Holdings LLC (lessee), BA Leasing BSC, LLC (lessor), Bank of America, N.A. (administrative agent), various lenders, and Regeneron Pharmaceuticals, Inc. along with its subsidiaries Regeneron Healthcare Solutions, Inc. and Regeneron Genetics Center LLC as guarantors.

The filing states that the agreements have been amended and restated, implying updates to the terms. However, the specific details of these changes beyond the procedural update are not provided in this 8-K. Investors would need to refer to the specific agreements (Exhibits 10.1, 10.2, 10.3) for detailed changes.